CU20170001A7 - Composiciones farmacéuticas de polímero de ácido nucleico fosforotioato y de nucleósido/nucleótido análogo, útiles para el tratamiento de hepatitis b y hepatitis d - Google Patents

Composiciones farmacéuticas de polímero de ácido nucleico fosforotioato y de nucleósido/nucleótido análogo, útiles para el tratamiento de hepatitis b y hepatitis d

Info

Publication number
CU20170001A7
CU20170001A7 CUP2017000001A CU20170001A CU20170001A7 CU 20170001 A7 CU20170001 A7 CU 20170001A7 CU P2017000001 A CUP2017000001 A CU P2017000001A CU 20170001 A CU20170001 A CU 20170001A CU 20170001 A7 CU20170001 A7 CU 20170001A7
Authority
CU
Cuba
Prior art keywords
hepatitis
nucleic acid
treatment
acid polymer
phosphorotioate
Prior art date
Application number
CUP2017000001A
Other languages
English (en)
Spanish (es)
Inventor
Andrew Vaillant
Original Assignee
Replicor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55063440&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CU20170001(A7) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Replicor Inc filed Critical Replicor Inc
Publication of CU20170001A7 publication Critical patent/CU20170001A7/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
CUP2017000001A 2014-07-10 2017-01-05 Composiciones farmacéuticas de polímero de ácido nucleico fosforotioato y de nucleósido/nucleótido análogo, útiles para el tratamiento de hepatitis b y hepatitis d CU20170001A7 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462022846P 2014-07-10 2014-07-10
US201462091943P 2014-12-15 2014-12-15
PCT/CA2015/050626 WO2016004525A1 (en) 2014-07-10 2015-07-07 Methods for the treatment of hepatitis b and hepatitis d virus infections

Publications (1)

Publication Number Publication Date
CU20170001A7 true CU20170001A7 (es) 2017-04-05

Family

ID=55063440

Family Applications (1)

Application Number Title Priority Date Filing Date
CUP2017000001A CU20170001A7 (es) 2014-07-10 2017-01-05 Composiciones farmacéuticas de polímero de ácido nucleico fosforotioato y de nucleósido/nucleótido análogo, útiles para el tratamiento de hepatitis b y hepatitis d

Country Status (33)

Country Link
US (1) US9603865B2 (enExample)
EP (1) EP3166615B1 (enExample)
JP (2) JP2017521433A (enExample)
KR (2) KR102734495B1 (enExample)
CN (2) CN113750112A (enExample)
AU (1) AU2015286199B2 (enExample)
BR (1) BR112017000320B1 (enExample)
CA (1) CA2954182C (enExample)
CL (1) CL2017000008A1 (enExample)
CU (1) CU20170001A7 (enExample)
DK (1) DK3166615T3 (enExample)
DO (1) DOP2017000002A (enExample)
EA (1) EA036745B1 (enExample)
EC (1) ECSP16097355A (enExample)
ES (1) ES2963814T3 (enExample)
FI (1) FI3166615T3 (enExample)
HK (1) HK1231402A1 (enExample)
HR (1) HRP20231400T1 (enExample)
HU (1) HUE064449T2 (enExample)
IL (1) IL249660B (enExample)
LT (1) LT3166615T (enExample)
MD (1) MD4760C8 (enExample)
MX (1) MX381042B (enExample)
MY (1) MY178087A (enExample)
PH (1) PH12017500010B1 (enExample)
PL (1) PL3166615T3 (enExample)
PT (1) PT3166615T (enExample)
RS (1) RS64833B1 (enExample)
SG (1) SG11201700073PA (enExample)
SI (1) SI3166615T1 (enExample)
SM (1) SMT202300380T1 (enExample)
TW (1) TWI766831B (enExample)
WO (1) WO2016004525A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112021008539A2 (pt) * 2018-11-08 2021-08-03 Aligos Therapeutics, Inc. polímeros de oligonucleotídeos e métodos de inibição de transporte de antígeno s
US11166976B2 (en) 2018-11-08 2021-11-09 Aligos Therapeutics, Inc. S-antigen transport inhibiting oligonucleotide polymers and methods
WO2021119325A1 (en) * 2019-12-12 2021-06-17 Aligos Therapeutics, Inc. S-antigen transport inhibiting oligonucleotide polymers and methods
CN113651853A (zh) * 2020-05-07 2021-11-16 西安新通药物研究股份有限公司 甲磺酸帕拉德福韦c晶型及其应用
WO2021223398A1 (zh) * 2020-05-07 2021-11-11 西安新通药物研究股份有限公司 治疗肝病的晶型及其应用
CN114057816B (zh) * 2020-07-30 2025-02-11 浙江柏拉阿图医药科技有限公司 富含腺嘌呤硫代磷酸酯化寡核苷酸及其抗肝炎病毒的应用
CA3200094A1 (en) * 2020-11-20 2022-05-27 Aligos Therapeutics, Inc. Conjugates of s-antigen transport inhibiting oligonucleotide polymers having enhanced liver targeting
WO2022133230A1 (en) 2020-12-18 2022-06-23 Janssen Pharmaceuticals, Inc. Combination therapy for treating hepatitis b virus infection
WO2022152869A1 (en) 2021-01-15 2022-07-21 Janssen Sciences Ireland Unlimited Company Use of oligonucleotides for individuals with hepatic impairment
WO2022261046A1 (en) * 2021-06-07 2022-12-15 Antios Therapeutics, Inc. Compositions and methods of treating hepatitis d and hepatitis b/hepatitis d co-infections with phosphoramidate clevudine prodrugs
WO2023281434A1 (en) 2021-07-09 2023-01-12 Janssen Pharmaceuticals, Inc. Use of oligonucleotides for individuals with renal impairment

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5482836A (en) * 1993-01-14 1996-01-09 The Regents Of The University Of California DNA purification by triplex-affinity capture and affinity capture electrophoresis
EP1537208A1 (en) 2002-09-13 2005-06-08 Replicor, Inc. Non-sequence complementary antiviral oligonucleotides
US9474793B2 (en) * 2005-02-22 2016-10-25 The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Vaccines and methods for prevention and treatment of drug-resistant HIV-1 and hepatitis B virus
NZ606364A (en) 2010-08-20 2014-12-24 Replicor Inc Oligonucleotide chelate complexes
DK2632472T3 (en) * 2010-10-29 2018-03-19 Sirna Therapeutics Inc RNA INTERFERENCE-MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERRING NUCLEIC ACIDS (SINA)
WO2012075114A2 (en) * 2010-12-01 2012-06-07 Ablitech, Inc. Nucleic acid-polymer conjugates and uses thereof
AR091065A1 (es) * 2012-05-18 2014-12-30 Replicor Inc Una formulacion farmaceutica que comprende un quelato de oligonucleotidos antiviral para el tratamiento de una infeccion antiviral
MY168778A (en) 2012-05-18 2018-12-04 Replicor Inc Oligonucleotide chelate complex-polypeptide compositions and methods
IN2015DN01087A (enExample) * 2012-08-30 2015-06-26 Replicor Inc

Also Published As

Publication number Publication date
EP3166615B1 (en) 2023-08-09
MX2017000053A (es) 2017-05-01
FI3166615T3 (fi) 2023-11-06
AU2015286199B2 (en) 2020-05-14
PT3166615T (pt) 2023-11-13
IL249660B (en) 2022-02-01
IL249660A0 (en) 2017-02-28
RS64833B1 (sr) 2023-12-29
ECSP16097355A (es) 2017-03-31
JP2017521433A (ja) 2017-08-03
CA2954182C (en) 2023-08-15
CL2017000008A1 (es) 2017-06-09
MY178087A (en) 2020-10-02
CN106659730A (zh) 2017-05-10
DK3166615T3 (da) 2023-11-13
LT3166615T (lt) 2024-01-25
CA2954182A1 (en) 2016-01-14
PH12017500010A1 (en) 2017-05-15
EP3166615A1 (en) 2017-05-17
PH12017500010B1 (en) 2022-07-29
DOP2017000002A (es) 2017-03-15
KR20170029577A (ko) 2017-03-15
JP2020143065A (ja) 2020-09-10
TWI766831B (zh) 2022-06-11
JP6922030B2 (ja) 2021-08-18
MD4760B1 (ro) 2021-07-31
US9603865B2 (en) 2017-03-28
EA201790160A1 (ru) 2017-06-30
EP3166615A4 (en) 2018-01-17
WO2016004525A1 (en) 2016-01-14
MD20170014A2 (ro) 2017-07-31
BR112017000320B1 (pt) 2023-02-07
HK1231402A1 (zh) 2017-12-22
KR102734495B1 (ko) 2024-11-25
BR112017000320A2 (pt) 2017-11-07
MD4760C8 (ro) 2022-02-28
US20160008393A1 (en) 2016-01-14
NZ727583A (en) 2024-08-30
HRP20231400T1 (hr) 2024-02-16
CN113750112A (zh) 2021-12-07
PL3166615T3 (pl) 2024-02-19
AU2015286199A1 (en) 2017-02-23
SI3166615T1 (sl) 2023-12-29
SG11201700073PA (en) 2017-02-27
SMT202300380T1 (it) 2024-01-10
ES2963814T3 (es) 2024-04-02
HUE064449T2 (hu) 2024-03-28
KR20230070330A (ko) 2023-05-22
EA036745B1 (ru) 2020-12-16
MX381042B (es) 2025-03-12
TW201613617A (en) 2016-04-16

Similar Documents

Publication Publication Date Title
CU20170001A7 (es) Composiciones farmacéuticas de polímero de ácido nucleico fosforotioato y de nucleósido/nucleótido análogo, útiles para el tratamiento de hepatitis b y hepatitis d
WO2017019891A3 (en) Compositions and methods for silencing hepatitis b virus gene expression
PH12017500614A1 (en) Compositions and methods for silencing hepatitis b virus gene expression
WO2017191258A8 (en) INFLUENZA MRNA VACCINES
MX2017016425A (es) Terapia con desoxinucleosidos para enfermedades generadas por grupos de nucleotidos desequilibrados, inclusive sindromes de agotamiento del adn mitocondrial.
WO2016183366A3 (en) Compositions and methods for silencing expression of hepatitis d virus rna
MX421406B (es) Composiciones de acido ribonucleico de interferencia (arni) contra el virus de la hepatitis b (hbv) y metodos de uso de estas
WO2017027350A3 (en) Rnai therapy for hepatitis b virus infection
MX373703B (es) Derivados de azepano y metodos para tratar infecciones por hepatitis b.
WO2015170322A3 (en) Compositions and methods of using same for increasing resistance of infected mosquitoes
ECSP15007345A (es) Métodos para el tratamiento de infecciones de hepatitis b y hepatitis d
AR111908A1 (es) Composiciones terapéuticas y métodos de tratamiento de hepatitis b
MX2018004797A (es) Formulacion de liberacion prolongada a base de un compuesto de hidrogel.
MX2018003290A (es) Medios para el tratamiento del vih.
AR106057A1 (es) Composición con efecto antiviral, composición farmacéutica
CL2017001160A1 (es) Combinación de composiciones de acción prolongada y métodos para la hepatitis c
CL2017001161A1 (es) Composiciones farmacéuticas de acción prolongada para la hepatitis c
AR101126A1 (es) Composiciones para el tratamiento de infecciones por virus de hepatitis b y hepatitis d
Karpinski et al. Universal Tre (uTre) recombinase specifically targets the majority of HIV‐1 isolates
MX2022006122A (es) Oligonucleótido de doble hebra específico del gen ctgf, y una composición que comprende el mismo, para prevenir y tratar enfermedades fibróticas y enfermedades relacionadas con el sistema respiratorio.
BR112019012057A2 (pt) agente antiviral, composição farmacêutica para a administração do mesmo e métodos de redução na replicação do vírus zika (zikv) e tratamento de doença mediada pelo vírus zika (zikv)
NZ727583B2 (en) Methods for the treatment of hepatitis b and hepatitis d virus infections
AR105532A1 (es) Composiciones y métodos para silenciar la expresión génica del virus de la hepatitis b
AR092396A1 (es) Compuestos utiles para el tratamiento de enfermedades infecciosas bacterianas